TNGX · Tango Therapeutics Inc
United States · RS rating 61 · As of 2026-11-03
| Price | 23.17 USD |
|---|---|
| 1-day change | +6.5% |
| RS rating (overall / 1M / 3M / 12M) | 61 / 58 / 32 / 97 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 37 / 23 / 29 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -323.1% |
| Sales growth Q/Q | -100.0% |
| Distance from 52-week high | +29.6% |
| Market cap (USD) | $3.7B |